Impact of peripheral arterial disease in patients with diabetes-Results from PROactive (PROactive 11)

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 272-281

  Dormandy, J A ^a   Betteridge, D J ^b   Schernthaner, G ^c   Pirags, V ^d   Norgren, L ^e  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^d PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus; Peripheral arterial disease; Pioglitazone; PROactive; Thiazolidinedione

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; NITRATE; PIOGLITAZONE; PLACEBO; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; AMPUTATION; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLAUDICATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ADULT; AGED; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLACEBOS; PROGNOSIS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 57649213646     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.03.002     Document Type: Article

References (40)

1. Roper N.A., Bilous R.W., Kelly W.F., et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 322 (2005) 1389-1393
2. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 26 (2003) 3333-3341
3. Selvin E., and Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 110 (2004) 738-743
4. Fine J.J., Hall P.A., and Richardson J.H. Predictive power of cardiovascular risk factors for detecting peripheral vascular disease. South Med J 97 (2004) 951-954
5. Walters D.P., Gatling W., Mullee M.A., et al. The prevalence, detection, and epidemiological correlates of peripheral vascular disease: a comparison of diabetic and non-diabetic subjects in an English community. Diabet Med 9 (1992) 710-715
6. Kallio M., Forsblom C., Groop P.H., et al. Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care 26 (2003) 1241-1245
7. Al-Delaimy W.K., Merchant A.T., Rimm E.B., et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 116 (2004) 236-240
8. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 32 (1992) 381-386
9. Bainton D., Sweetnam P., Baker I., et al. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 72 (1994) 128-132
10. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
11. Nikolsky E., Mehran R., Dangas G.D., et al. Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions. Am J Cardiol 93 (2004) 1536-1539
12. Guerrero M., Harjai K., Stone G.W., et al. Usefulness of the presence of peripheral vascular disease in predicting mortality in acute myocardial infarction patients treated with primary angioplasty (from the primary angioplasty in myocardial infarction database). Am J Cardiol 96 (2005) 649-654
13. Lange S., Diehm C., Darius H., et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes 112 (2004) 566-573
14. Okaa R.K., Umoh E., Szuba A., et al. Suboptimal intensity of risk factor modification in PAD. Vasc Med 10 (2005) 91-96
15. Rehring T.F., Sandhoff B.G., Stolcpart R.S., et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 41 (2005) 816-822
16. Dormandy J.A., Charbonnel B., Eckland D.J., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
17. Derosa G., Cicero A.F., Bertone G., et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a 12-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 26 (2004) 744-754
18. Peters Harmel A.L., Kendall D.M., Buse J.B., et al. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 20 (2004) 215-223
19. Schernthaner G., Matthews D., Charbonnel B., et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89 (2004) 6068-6076
20. Betteridge D.J., and Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 48 (2005) 247-248
21. Charbonnel B., Schernthaner G., Brunetti P., et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 48 (2005) 1093-1104
22. Goldberg R.B., Kendall D.M., Deeg M.A., et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
23. Staels B. PPARγ and atherosclerosis. Curr Med Res Opin 21 (2005) S13-S20
24. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effects of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
25. Wilcox R., Bousser M.G., Betteridge J., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke-results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events; PROactive). Stroke 38 (2007) 865-873
26. Erdmann E., Dormandy J.A., Charbonnel B.J., et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study). J Am Coll Cardiol 49 (2007) 1772-1780
27. Charbonnel B., Dormandy J., Erdmann E., et al. PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27 (2004) 1647-1653
28. Anon. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 16 (1999) 716-730
29. Rehring T.F., Stolcpart R.S., Sandhoff B.G., et al. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg 43 (2006) 1205-1210
30. Kjekshus J., and Pedersen T.R. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76 (1995) 64C-68C
31. Heart Protection Study Collaboration Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
32. Shepherd J., Blauw G.J., Murphy M.B., et al. On behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
33. Adler A.I., Stevens R.J., Neil A., et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25 (2002) 894-899
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
35. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
36. Arboix A., Rivas A., Garcia-Eroles L., et al. Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and predictors of in-hospital mortality. BMC Neurol 5 (2005) 9
37. Khan U., Porteous L., Hassan A., and Markus H. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 78 (2007) 702-706
38. Lange S., Trampisch H.J., Haberl R., et al. Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level. Atherosclerosis 178 (2005) 351-357
39. Mayfield J.A., Reiber G.E., Sanders L.J., et al. Preventive foot care in people with diabetes. Diabetes Care 21 (1998) 2161-2177
40. Mudaliar S., Chang A.R., and Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9 (2003) 406-416